About cGMP-dependent 3',5'-cyclic phosphodiesterase
cGMP-dependent 3',5'-cyclic phosphodiesterase (PDE2A) is a protein
from Homo sapiens identified by UniProt accession
O00408, 941 residues long.
MolForge cross-references it against 0 known binders and
238 disease associations.
Target properties
| Protein name | cGMP-dependent 3',5'-cyclic phosphodiesterase |
|---|
| UniProt accession | O00408 |
|---|
| Gene | PDE2A |
|---|
| Organism | Homo sapiens |
|---|
| Length | 941 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Approved drugs hitting this target (7)
DrugCentral-linked approved drugs that act on this protein.
Disease associations (238)
Diseases linked to this target (Open Targets).
- intellectual developmental disorder with paroxysmal dyskinesia or seizures · score 0.67
- coronary artery disease · score 0.55
- stroke · score 0.55
- Hepatitis, Alcoholic · score 0.48
- diabetes mellitus · score 0.48
- diabetic nephropathy · score 0.47
- chronic kidney disease · score 0.47
- Myocardial Ischemia · score 0.47
- non-alcoholic steatohepatitis · score 0.45
- testosterone measurement · score 0.45
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-O00408-F1 | alphafold | PREDICTED | 83.67 | — |
Amino-acid sequence (941 residues)
MGQACGHSIL CRSQQYPAAR PAEPRGQQVF LKPDEPPPPP QPCADSLQDA LLSLGSVIDI SGLQRAVKEA LSAVLPRVET VYTYLLDGES QLVCEDPPHE LPQEGKVREA IISQKRLGCN GLGFSDLPGK PLARLVAPLA PDTQVLVMPL ADKEAGAVAA VILVHCGQLS DNEEWSLQAV EKHTLVALRR VQVLQQRGPR EAPRAVQNPP EGTAEDQKGG AAYTDRDRKI LQLCGELYDL DASSLQLKVL QYLQQETRAS RCCLLLVSED NLQLSCKVIG DKVLGEEVSF PLTGCLGQVV EDKKSIQLKD LTSEDVQQLQ SMLGCELQAM LCVPVISRAT DQVVALACAF NKLEGDLFTD EDEHVIQHCF HYTSTVLTST LAFQKEQKLK CECQALLQVA KNLFTHLDDV SVLLQEIITE ARNLSNAEIC SVFLLDQNEL VAKVFDGGVV DDESYEIRIP ADQGIAGHVA TTGQILNIPD AYAHPLFYRG VDDSTGFRTR NILCFPIKNE NQEVIGVAEL VNKINGPWFS KFDEDLATAF SIYCGISIAH SLLYKKVNEA QYRSHLANEM MMYHMKVSDD EYTKLLHDGI QPVAAIDSNF ASFTYTPRSL PEDDTSMAIL SMLQDMNFIN NYKIDCPTLA RFCLMVKKGY RDPPYHNWMH AFSVSHFCYL LYKNLELTNY LEDIEIFALF ISCMCHDLDH RGTNNSFQVA SKSVLAALYS SEGSVMERHH FAQAIAILNT HGCNIFDHFS RKDYQRMLDL MRDIILATDL AHHLRIFKDL QKMAEVGYDR NNKQHHRLLL CLLMTSCDLS DQTKGWKTTR KIAELIYKEF FSQGDLEKAM GNRPMEMMDR EKAYIPELQI SFMEHIAMPI YKLLQDLFPK AAELYERVAS NREHWTKVSH KFTIRGLPSN NSLDFLDEEY EVPDLDGTRA PINGCCSLDA E
Explore cGMP-dependent 3',5'-cyclic phosphodiesterase with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets